JP2023539246A5 - - Google Patents
Info
- Publication number
- JP2023539246A5 JP2023539246A5 JP2023513297A JP2023513297A JP2023539246A5 JP 2023539246 A5 JP2023539246 A5 JP 2023539246A5 JP 2023513297 A JP2023513297 A JP 2023513297A JP 2023513297 A JP2023513297 A JP 2023513297A JP 2023539246 A5 JP2023539246 A5 JP 2023539246A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- cancer
- compound
- formula
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063070173P | 2020-08-25 | 2020-08-25 | |
| US63/070,173 | 2020-08-25 | ||
| PCT/US2021/047380 WO2022046792A2 (en) | 2020-08-25 | 2021-08-24 | Methods and compositions for genetic modulation of tumor microenvironments |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023539246A JP2023539246A (ja) | 2023-09-13 |
| JP2023539246A5 true JP2023539246A5 (cg-RX-API-DMAC7.html) | 2024-09-02 |
Family
ID=80355668
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023513297A Pending JP2023539246A (ja) | 2020-08-25 | 2021-08-24 | 腫瘍微小環境の遺伝的調節のための方法及び組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220110924A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4203955A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023539246A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230057426A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021333655A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023003466A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3190514A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023002286A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022046792A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202302154B (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4654979A1 (en) * | 2023-01-25 | 2025-12-03 | Huyabio International, LLC | Methods and compositions comprising a cardio-tolerated hdac inhibitor |
| CN117357530A (zh) * | 2023-11-07 | 2024-01-09 | 苏州大学附属儿童医院 | Pde3a抑制剂在制备治疗急性髓系白血病的药物中的应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7244751B2 (en) * | 2003-02-14 | 2007-07-17 | Shenzhen Chipscreen Biosciences Ltd. | Histone deacetylase inhibitors of novel benzamide derivatives with potent differentiation and anti-proliferation activity |
| TWI794171B (zh) * | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
| TWI808055B (zh) * | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TR201900059A2 (tr) * | 2018-01-05 | 2019-07-22 | Gnt Biotech & Medicals Corp | Bi̇r farmasöti̇k kombi̇nasyon ve tümör mi̇kroortaminin ve i̇mmünoterapi̇ni̇n regülasyonu i̇çi̇n yöntem |
-
2021
- 2021-08-24 AU AU2021333655A patent/AU2021333655A1/en active Pending
- 2021-08-24 KR KR1020237010117A patent/KR20230057426A/ko active Pending
- 2021-08-24 MX MX2023002286A patent/MX2023002286A/es unknown
- 2021-08-24 CA CA3190514A patent/CA3190514A1/en active Pending
- 2021-08-24 JP JP2023513297A patent/JP2023539246A/ja active Pending
- 2021-08-24 BR BR112023003466A patent/BR112023003466A2/pt unknown
- 2021-08-24 WO PCT/US2021/047380 patent/WO2022046792A2/en not_active Ceased
- 2021-08-24 EP EP21862586.1A patent/EP4203955A4/en active Pending
- 2021-08-24 US US17/410,459 patent/US20220110924A1/en active Pending
-
2023
- 2023-02-21 ZA ZA2023/02154A patent/ZA202302154B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12428486B2 (en) | Chimeric antigen receptors specific for B-cell maturation antigen and encoding polynucleotides | |
| JP2024023317A (ja) | 二重特異性抗体の組成物及びその使用方法 | |
| JP2023530408A (ja) | Cd70指向性がん免疫療法のための遺伝子修飾されたナチュラルキラー細胞 | |
| CA3117419A1 (en) | Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen | |
| JP2022507295A5 (cg-RX-API-DMAC7.html) | ||
| JP2017530694A5 (cg-RX-API-DMAC7.html) | ||
| CN107847587A (zh) | Cd30×cd16抗体与pd‑1拮抗剂的联合药物用于治疗 | |
| AU2020271012A1 (en) | Humanized anti-DLL3 chimeric antigen receptors and uses thereof | |
| WO2020205331A1 (en) | Humanized anti-claudin 18.2 chimeric antigen receptors and uses thereof | |
| US20220162301A1 (en) | Humanized anti-folate receptor 1 chimeric antigen receptors and uses thereof | |
| JP2022535410A (ja) | Taciを標的とする抗体及びキメラ抗原受容体 | |
| CA3244124A1 (en) | Anti-mesothelin antibodies and their uses | |
| WO2021226321A2 (en) | Anti-tumor associated antigen antibodies and uses thereof | |
| WO2018132508A1 (en) | Methods and compositions relating to ex vivo culture and modulation of t cells | |
| US20230338422A1 (en) | Engineering gamma delta t cells with interleukin-36 for immunotherapy | |
| KR20240127523A (ko) | 항-cntn4 항체 및 그의 용도 | |
| US20260109774A1 (en) | Chimeric antigen receptors specific for b-cell maturation antigen and encoding polynucleotides | |
| US20250136703A1 (en) | Anti-il13ra2 antibodies and uses thereof | |
| WO2025147472A1 (en) | Anti-611-ctf p95her2 antibodies and uses thereof | |
| WO2024076864A2 (en) | Anti-ror1 antibodies and uses thereof | |
| WO2026015853A1 (en) | Enhancing activity and persistence of car-nk cells for the treatment of cancer and autoimmune diseases | |
| HK40117638A (en) | Human antibodies against fap-alpha | |
| WO2024182475A2 (en) | Anti-ror2 antibodies and uses thereof | |
| EP4608444A2 (en) | Anti-egfrviii antibodies and uses thereof | |
| EP4615501A1 (en) | Anti-5t4 antibodies and uses thereof |